CU-CPT-9a - Toll-like Receptor (TLR) Antagonist - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECU-CPT-9aCat. No.: HY-112667CAS No.: 2165340-32-7分式: CHNO分量: 265.31作靶點: Toll-like Receptor (TLR)作通路: Immunology/Inflammation儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 150 mg/mL (565.38

2、 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.7692 mL 18.8459 mL 37.6918 mL5 mM 0.7538 mL 3.7692 mL 7.5384 mL10 mM 0.3769 mL 1.8846 mL 3.7692 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當天使；澄清的

3、儲備液可以根據(jù)儲存條件，適當保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (9.42 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (9.42 mM); Clear solution3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL

4、(9.42 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 CU-CPT-9a是TLR8 的特異性拮抗劑，其 IC50 值為 0.5 nM。IC50 & Target TLR80.5 nM (IC50)體外研究 CU-CPT-9a is a specific TLR8 antagonist, with an IC50 of 0.50.1 nM. The elevation of the downstreamprotein levels induced by R8

5、48 can be reversed by CU-CPT-9a in a dose-dependent manner. By contrast,the expression of TRIF and IRF3 (cytoplasmic and nuclear) are only responsive to TLR4 and TLR3,independent of TLR837. The expression levels of TRIF and IRF3 do not show significant change in THP-1cells upon treatment of R848, no

6、r do they change with the treatment of CU-CPT-9a. CU-CPT8m and CU-CPT-9a both significantly suppress the TNF- level in a dose-dependent manner, which is in agreement withprevious reports of TLR8 involvement in these autoimmune diseases 1.戶使本產(chǎn)品發(fā)表的科研獻 Eur J Pharmacol. 2019 Mar 5;846:12-22.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018 Jan;14(1):58-64.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use on